A multi-centred, randomized, double blinded and placebo controlled treatment effectiveness Phase III clinical trial for early stage Parkinson's disease patients

Trial Profile

A multi-centred, randomized, double blinded and placebo controlled treatment effectiveness Phase III clinical trial for early stage Parkinson's disease patients

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2018 New trial record
    • 12 Apr 2018 According to a Luye Pharma media release, the company has reached a consensus with the centre for drug evaluation (CDE) of China Food and Drug Administration and is exempted from Phase II dosage exploration clinical trials for LY03003 and can directly commence Phase III trials.
    • 10 Apr 2018 According to a Luye Pharma media release, the company has obtained the approval from the China Food and Drug Administration (CFDA) to proceed with this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top